The DOI matches its Crossref record; 198 of the 198 references it cites were found in a registry or an index.
Clinical cancer nanomedicine
Open accessAbstract
Nanotechnology offers new solutions for the development of cancer therapeutics that display improved efficacy and safety. Although several nanotherapeutics have received clinical approval, the most promising nanotechnology applications for patients still lie ahead. Nanoparticles display unique transport, biological, optical, magnetic, electronic, and thermal properties that are not apparent on the molecular or macroscale, and can be utilized for therapeutic purposes. These characteristics arise because nanoparticles are in the same size range as the wavelength of light and display large surface area to volume ratios. The large size of nanoparticles compared to conventional chemotherapeutic agents or biological macromolecule drugs also enables incorporation of several supportive components in addition to active pharmaceutical ingredients. These components can facilitate solubilization, protection from degradation, sustained release, immunoevasion, tissue penetration, imaging, targeting, and triggered activation. Nanoparticles are also processed differently in the body compared to conventional drugs. Specifically, nanoparticles display unique hemodynamic properties and biodistribution profiles. Notably, the interactions that occur at the bio-nano interface can be exploited for improved drug delivery. This review discusses successful clinically approved cancer nanodrugs as well as promising candidates in the pipeline. These nanotherapeutics are categorized according to whether they predominantly exploit multifunctionality, unique electromagnetic properties, or distinct transport characteristics in the body. Moreover, future directions in nanomedicine such as companion diagnostics, strategies for modifying the microenvironment, spatiotemporal nanoparticle transitions, and the use of extracellular vesicles for drug delivery are also explored.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Théry, C., Witwer, K. W., Aikawa, E., Alcaraz, M. J., Anderson, J. D., Andriantsitohaina, R., Antoniou, A., Arab, T., Archer, F., Atkin‐Smith, G. K., et al. (2018) · Journal of Extracellular Vesicles · doi:10.1080/20013078.2018.1535750 · Cited by 11,099
Self-citationMatsumura, Y., & Maeda, H. (1986) · PubMed · Cited by 6,781
Recognition of double-stranded RNA and activation of NF-κB by Toll-like receptor 3
Alexopoulou, L., Holt, A. C., Medzhitov, R., & Flavell, R. A. (2001) · Nature · doi:10.1038/35099560 · Cited by 6,129
Cancer nanomedicine: progress, challenges and opportunities
Shi, J., Kantoff, P. W., Wooster, R., & Farokhzad, O. C. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2016.108 · Cited by 5,873
Doxil® — The first FDA-approved nano-drug: Lessons learned
Barenholz, Y. (. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.03.020 · Cited by 4,792
Kalluri, R., & Zeisberg, M. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1877 · Cited by 4,538
Renal clearance of quantum dots
Soo Choi, H., Liu, W., Misra, P., Tanaka, E., Zimmer, J. P., Itty Ipe, B., Bawendi, M. G., & Frangioni, J. V. (2007) · Nature Biotechnology · doi:10.1038/nbt1340 · Cited by 4,476
Nanoshell-mediated near-infrared thermal therapy of tumors under magnetic resonance guidance
Hirsch, L. R., Stafford, R. J., Bankson, J. A., Sershen, S. R., Rivera, B., Price, R. E., Hazle, J. D., Halas, N. J., & West, J. L. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2232479100 · Cited by 3,955
Extracellular vesicles: biology and emerging therapeutic opportunities
EL Andaloussi, S., Mäger, I., Breakefield, X. O., & Wood, M. J. A. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd3978 · Cited by 3,571
Fang, J., Nakamura, H., & Maeda, H. (2011) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2010.04.009 · Cited by 3,559
Poly(ethylene glycol) in Drug Delivery: Pros and Cons as Well as Potential Alternatives
Knop, K., Hoogenboom, R., Fischer, D., & Schubert, U. S. (2010) · Angewandte Chemie International Edition · doi:10.1002/anie.200902672 · Cited by 3,533
Lundqvist, M., Stigler, J., Elia, G., Lynch, I., Cedervall, T., & Dawson, K. A. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0805135105 · Cited by 2,823
Drug penetration in solid tumours
Minchinton, A. I., & Tannock, I. F. (2006) · Nature reviews. Cancer · doi:10.1038/nrc1893 · Cited by 2,805
Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer
Kamerkar, S., LeBleu, V. S., Sugimoto, H., Yang, S., Ruivo, C. F., Melo, S. A., Lee, J. J., & Kalluri, R. (2017) · Nature · doi:10.1038/nature22341 · Cited by 2,639
Erythrocyte membrane-camouflaged polymeric nanoparticles as a biomimetic delivery platform
Hu, C.-M. J., Zhang, L., Aryal, S., Cheung, C., Fang, R. H., & Zhang, L. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1106634108 · Cited by 2,433
Gradishar, W. J., Tjulandin, S., Davidson, N., Shaw, H., Desai, N., Bhar, P., Hawkins, M., & O'Shaughnessy, J. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.937 · Cited by 2,153
Tumor delivery of macromolecular drugs based on the EPR effect
Torchilin, V. (2011) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2010.03.011 · Cited by 2,032
Human serum albumin: From bench to bedside
Fanali, G., di Masi, A., Trezza, V., Marino, M., Fasano, M., & Ascenzi, P. (2012) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2011.12.002 · Cited by 1,931
Salvati, A., Pitek, A. S., Monopoli, M. P., Prapainop, K., Bombelli, F. B., Hristov, D. R., Kelly, P. M., Åberg, C., Mahon, E., & Dawson, K. A. (2013) · Nature Nanotechnology · doi:10.1038/nnano.2012.237 · Cited by 1,912
Nanomedicine in cancer therapy: Challenges, opportunities, and clinical applications
Wicki, A., Witzigmann, D., Balasubramanian, V., & Huwyler, J. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.12.030 · Cited by 1,901
Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy
Kranz, L. M., Diken, M., Haas, H., Kreiter, S., Loquai, C., Reuter, K. C., Meng, M., Fritz, D., Vascotto, F., Hefesha, H., et al. (2016) · Nature · doi:10.1038/nature18300 · Cited by 1,819
Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size.
Yuan, F., Dellian, M., Fukumura, D., Leunig, M., Berk, D. A., Torchilin, V. P., & Jain, R. K. (1995) · PubMed · Cited by 1,711
Ligand-targeted therapeutics in anticancer therapy
Allen, T. M. (2002) · Nature Reviews Cancer · doi:10.1038/nrc903 · Cited by 1,647
Prabhakar, U., Maeda, H., Jain, R. K., Sevick-Muraca, E. M., Zamboni, W., Farokhzad, O. C., Barry, S. T., Gabizon, A., Grodzinski, P., & Blakey, D. C. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-4561 · Cited by 1,485
Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies
Naidoo, J., Page, D. B., Li, B. T., Connell, L. C., Schindler, K., Lacouture, M. E., Postow, M. A., & Wolchok, J. D. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv383 · Cited by 1,470
Maier-Hauff, K., Ulrich, F., Nestler, D., Niehoff, H., Wust, P., Thiesen, B., Orawa, H., Budach, V., & Jordan, A. (2011) · Journal of Neuro-Oncology · doi:10.1007/s11060-010-0389-0 · Cited by 1,429
Nanoparticle uptake: The phagocyte problem
Gustafson, H. H., Holt-Casper, D., Grainger, D. W., & Ghandehari, H. (2015) · Nano Today · doi:10.1016/j.nantod.2015.06.006 · Cited by 1,411
Nanoparticle–liver interactions: Cellular uptake and hepatobiliary elimination
Zhang, Y.-N., Poon, W., Tavares, A. J., McGilvray, I. D., & Chan, W. C. W. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.01.020 · Cited by 1,349
Anselmo, A. C., & Mitragotri, S. (2016) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10003 · Cited by 1,321
Escudier, B., Dorval, T., Chaput, N., André, F., Caby, M.-P., Novault, S., Flament, C., Leboulaire, C., Borg, C., Amigorena, S., et al. (2005) · Journal of Translational Medicine · doi:10.1186/1479-5876-3-10 · Cited by 1,280
Iversen, T.-G., Skotland, T., & Sandvig, K. (2011) · Nano Today · doi:10.1016/j.nantod.2011.02.003 · Cited by 1,239
Eph receptors and ephrins in cancer: bidirectional signalling and beyond
Pasquale, E. B. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2806 · Cited by 1,226
Challenges and strategies in anti-cancer nanomedicine development: An industry perspective
Hare, J. I., Lammers, T., Ashford, M. B., Puri, S., Storm, G., & Barry, S. T. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.04.025 · Cited by 1,214
Parodi, A., Quattrocchi, N., van de Ven, A. L., Chiappini, C., Evangelopoulos, M., Martinez, J. O., Brown, B. S., Khaled, S. Z., Yazdi, I. K., Enzo, M. V., et al. (2013) · Nature Nanotechnology · doi:10.1038/nnano.2012.212 · Cited by 1,168
Self-citationA phase I study of dexosome immunotherapy in patients with advanced non-small cell lung cancer
Morse, M. A., Garst, J., Osada, T., Khan, S., Hobeika, A., Clay, T. M., Valente, N., Shreeniwas, R., Sutton, M. A., Delcayre, A., et al. (2005) · Journal of Translational Medicine · doi:10.1186/1479-5876-3-9 · Cited by 1,120
Gardiner, C., Di Vizio, D., Sahoo, S., Théry, C., Witwer, K. W., Wauben, M., & Hill, A. F. (2016) · Journal of Extracellular Vesicles · doi:10.3402/jev.v5.32945 · Cited by 1,069
Multistage nanoparticle delivery system for deep penetration into tumor tissue
Wong, C., Stylianopoulos, T., Cui, J., Martin, J., Chauhan, V. P., Jiang, W., Popović, Z., Jain, R. K., Bawendi, M. G., & Fukumura, D. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1018382108 · Cited by 1,062
Rational Design of Cancer Nanomedicine: Nanoproperty Integration and Synchronization
Sun, Q., Zhou, Z., Qiu, N., & Shen, Y. (2017) · Advanced Materials · doi:10.1002/adma.201606628 · Cited by 1,058
Minimal "Self" Peptides That Inhibit Phagocytic Clearance and Enhance Delivery of Nanoparticles
Rodriguez, P. L., Harada, T., Christian, D. A., Pantano, D. A., Tsai, R. K., & Discher, D. E. (2013) · Science · doi:10.1126/science.1229568 · Cited by 985
RGD-Based Strategies To Target Alpha(v) Beta(3) Integrin in Cancer Therapy and Diagnosis
Danhier, F., Le Breton, A., & Préat, V. (2012) · Molecular Pharmaceutics · doi:10.1021/mp3002733 · Cited by 955
Sequence- and target-independent angiogenesis suppression by siRNA via TLR3
Kleinman, M. E., Yamada, K., Takeda, A., Chandrasekaran, V., Nozaki, M., Baffi, J. Z., Albuquerque, R. J. C., Yamasaki, S., Itaya, M., Pan, Y., et al. (2008) · Nature · doi:10.1038/nature06765 · Cited by 929
TUMOR DORMANCY IN VIVO BY PREVENTION OF NEOVASCULARIZATION
Gimbrone, M. A., Leapman, S. B., Cotran, R. S., & Folkman, J. (1972) · The Journal of Experimental Medicine · doi:10.1084/jem.136.2.261 · Cited by 903
Beg, M. S., Brenner, A. J., Sachdev, J., Borad, M., Kang, Y.-K., Stoudemire, J., Smith, S., Bader, A. G., Kim, S., & Hong, D. S. (2017) · Investigational New Drugs · doi:10.1007/s10637-016-0407-y · Cited by 897
Strategies for advancing cancer nanomedicine
Chauhan, V. P., & Jain, R. K. (2013) · Nature Materials · doi:10.1038/nmat3792 · Cited by 812
The transferrin receptor and the targeted delivery of therapeutic agents against cancer
Daniels, T. R., Bernabeu, E., Rodríguez, J. A., Patel, S., Kozman, M., Chiappetta, D. A., Holler, E., Ljubimova, J. Y., Helguera, G., & Penichet, M. L. (2012) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2011.07.016 · Cited by 807
Apolipoprotein-mediated transport of nanoparticle-bound drugs across the blood-brain barrier.
Kreuter, J., Shamenkov, D., Petrov, V., Ramge, P., Cychutek, K., Koch-Brandt, C., & Alyautdin, R. (2002) · Journal of drug targeting · doi:10.1080/10611860290031877 · Cited by 801
Protein nanoparticles as drug carriers in clinical medicine
Hawkins, M. J., Soon-Shiong, P., & Desai, N. (2008) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.08.044 · Cited by 779
Stimuli-responsive clustered nanoparticles for improved tumor penetration and therapeutic efficacy
Li, H.-J., Du, J.-Z., Du, X.-J., Xu, C.-F., Sun, C.-Y., Wang, H.-X., Cao, Z.-T., Yang, X.-Z., Zhu, Y.-H., Nie, S., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1522080113 · Cited by 724
State of the art in PEGylation: The great versatility achieved after forty years of research
Pasut, G., & Veronese, F. M. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.10.037 · Cited by 720
SMANCS and polymer-conjugated macromolecular drugs: advantages in cancer chemotherapy
Maeda, H. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00134-4 · Cited by 662
Using shape effects to target antibody-coated nanoparticles to lung and brain endothelium
Kolhar, P., Anselmo, A. C., Gupta, V., Pant, K., Prabhakarpandian, B., Ruoslahti, E., & Mitragotri, S. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1308345110 · Cited by 646
Microvascular permeability of normal and neoplastic tissues
Gerlowski, L. E., & Jain, R. K. (1986) · Microvascular Research · doi:10.1016/0026-2862(86)90018-x · Cited by 622
Siemann, D. W. (2011) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2010.05.001 · Cited by 611
Lundqvist, M., Sethson, I., & Jonsson, B.-H. (2004) · Langmuir · doi:10.1021/la0484725 · Cited by 597
Pharmacological Effects of Formulation Vehicles: Implications for Cancer Chemotherapy
ten Tije, A. J., Verweij, J., Loos, W. J., & Sparreboom, A. (2003) · Clinical Pharmacokinetics · doi:10.2165/00003088-200342070-00005 · Cited by 591
Harrington, K. J., Mohammadtaghi, S., Uster, P. S., Glass, D. M., Peters, A. M., Vile, R. G., & Stewart, J. S. W. (2001) · PubMed · Cited by 575
Wang, H.-X., Li, M., Lee, C. M., Chakraborty, S., Kim, H.-W., Bao, G., & Leong, K. W. (2017) · Chemical Reviews · doi:10.1021/acs.chemrev.6b00799 · Cited by 560
Li, H.-J., Du, J.-Z., Liu, J., Du, X.-J., Shen, S., Zhu, Y.-H., Wang, X., Ye, X., Nie, S., & Wang, J. (2016) · ACS Nano · doi:10.1021/acsnano.6b02326 · Cited by 537
Busatto, S., Vilanilam, G., Ticer, T., Lin, W.-L., Dickson, D. W., Shapiro, S., Bergese, P., & Wolfram, J. (2018) · Cells · doi:10.3390/cells7120273 · Cited by 532
Self-citationRecent advances in stealth coating of nanoparticle drug delivery systems
Amoozgar, Z., & Yeo, Y. (2012) · WIREs Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1157 · Cited by 528
Combining two strategies to improve perfusion and drug delivery in solid tumors
Stylianopoulos, T., & Jain, R. K. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1318415110 · Cited by 508
nab-Paclitaxel mechanisms of action and delivery
Yardley, D. A. (2013) · Journal of Controlled Release · doi:10.1016/j.jconrel.2013.05.041 · Cited by 508
Hatakeyama, H., Akita, H., & Harashima, H. (2013) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b13-00059 · Cited by 495
Extracellular vesicles as drug delivery systems: Lessons from the liposome field
van der Meel, R., Fens, M. H. A. M., Vader, P., van Solinge, W. W., Eniola-Adefeso, O., & Schiffelers, R. M. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.07.049 · Cited by 482
Chanan-Khan, A., Szebeni, J., Savay, S., Liebes, L., Rafique, N. M., Alving, C. R., & Muggia, F. M. (2003) · Annals of Oncology · doi:10.1093/annonc/mdg374 · Cited by 479
Prostate-specific membrane antigen is produced in tumor-associated neovasculature.
Chang, S. S., O’Keefe, D. S., Bacich, D. J., Reuter, V. E., Heston, W. D. W., & Gaudin, P. B. (1999) · PubMed · Cited by 471
Medicine, N. L. O. (2008) · Journal of Pain & Palliative Care Pharmacotherapy · doi:10.1080/15360280801989377 · Cited by 468
The adhesive strength of non-spherical particles mediated by specific interactions
Decuzzi, P., & Ferrari, M. (2006) · Biomaterials · doi:10.1016/j.biomaterials.2006.05.024 · Cited by 452
Self-citationComparative assessment of nanomaterial definitions and safety evaluation considerations
Boverhof, D. R., Bramante, C. M., Butala, J. H., Clancy, S. F., Lafranconi, M., West, J., & Gordon, S. C. (2015) · Regulatory Toxicology and Pharmacology · doi:10.1016/j.yrtph.2015.06.001 · Cited by 443
Tumour‐associated macrophages act as a slow‐release reservoir of nano‐therapeutic Pt(IV) pro‐drug
Miller, M. A., Zheng, Y.-R., Gadde, S., Pfirschke, C., Zope, H., Engblom, C., Kohler, R. H., Iwamoto, Y., Yang, K. S., Askevold, B., et al. (2015) · Nature Communications · doi:10.1038/ncomms9692 · Cited by 441
Untch, M., Jackisch, C., Schneeweiss, A., Conrad, B., Aktas, B., Denkert, C., Eidtmann, H., Wiebringhaus, H., Kümmel, S., Hilfrich, J., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00542-2 · Cited by 414
Lee, H., Shields, A. F., Siegel, B. A., Miller, K. D., Krop, I., Ma, C. X., LoRusso, P. M., Munster, P. N., Campbell, K., Gaddy, D. F., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-3193 · Cited by 393
Designing the nanoparticle–biomolecule interface for “targeting and therapeutic delivery”
Mahon, E., Salvati, A., Baldelli Bombelli, F., Lynch, I., & Dawson, K. A. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.04.009 · Cited by 385
Fibronectin, the extracellular glue
Zollinger, A. J., & Smith, M. L. (2017) · Matrix Biology · doi:10.1016/j.matbio.2016.07.011 · Cited by 383
Thermal ablation of tumor cells with antibody-functionalized single-walled carbon nanotubes
Chakravarty, P., Marches, R., Zimmerman, N. S., Swafford, A. D.-E., Bajaj, P., Musselman, I. H., Pantano, P., Draper, R. K., & Vitetta, E. S. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0803557105 · Cited by 374
Zhang, J., Landry, M. P., Barone, P. W., Kim, J.-H., Lin, S., Ulissi, Z. W., Lin, D., Mu, B., Boghossian, A. A., Hilmer, A. J., et al. (2013) · Nature Nanotechnology · doi:10.1038/nnano.2013.236 · Cited by 367
Liposomal paclitaxel formulations
Koudelka, Š., & Turánek, J. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.09.006 · Cited by 366
FDA Approves Eteplirsen for Duchenne Muscular Dystrophy: The Next Chapter in the Eteplirsen Saga
Aartsma-Rus, A., & Krieg, A. M. (2017) · Nucleic Acid Therapeutics · doi:10.1089/nat.2016.0657 · Cited by 364
Zhu, L., Wang, T., Perche, F., Taigind, A., & Torchilin, V. P. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1304987110 · Cited by 358
Tardi, P., Johnstone, S., Harasym, N., Xie, S., Harasym, T., Zisman, N., Harvie, P., Bermudes, D., & Mayer, L. (2009) · Leukemia Research · doi:10.1016/j.leukres.2008.06.028 · Cited by 356
An index for characterization of nanomaterials in biological systems
Xia, X.-R., Monteiro-Riviere, N. A., & Riviere, J. E. (2010) · Nature Nanotechnology · doi:10.1038/nnano.2010.164 · Cited by 352
Van der Veldt, A. A. M., Lubberink, M., Bahce, I., Walraven, M., de Boer, M. P., Greuter, H. N. J. M., Hendrikse, N. H., Eriksson, J., Windhorst, A. D., Postmus, P. E., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2011.11.023 · Cited by 337
Accelerated clearance of PEGylated liposomes in rats after repeated injections
Ishida, T., Maeda, R., Ichihara, M., Irimura, K., & Kiwada, H. (2003) · Journal of Controlled Release · doi:10.1016/s0168-3659(02)00462-5 · Cited by 327
A Pilot Study of the Telomerase Inhibitor Imetelstat for Myelofibrosis
Tefferi, A., Lasho, T. L., Begna, K. H., Patnaik, M. M., Zblewski, D. L., Finke, C. M., Laborde, R. R., Wassie, E., Schimek, L., Hanson, C. A., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1310523 · Cited by 325
Genetic heterogeneity of the vasculogenic phenotype parallels angiogenesis
Shaked, Y., Bertolini, F., Man, S., Rogers, M. S., Cervi, D., Foutz, T., Rawn, K., Voskas, D., Dumont, D. J., Ben-David, Y., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2004.11.023 · Cited by 324
Charrois, G. J. R., & Allen, T. M. (2004) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2004.03.006 · Cited by 300
Strategies to Inhibit Myc and Their Clinical Applicability
Whitfield, J. R., Beaulieu, M.-E., & Soucek, L. (2017) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2017.00010 · Cited by 294
Zhou, H., Fan, Z., Deng, J., Lemons, P. K., Arhontoulis, D. C., Bowne, W. B., & Cheng, H. (2016) · Nano Letters · doi:10.1021/acs.nanolett.6b00820 · Cited by 293
Von Hoff, D. D., Mita, M. M., Ramanathan, R. K., Weiss, G. J., Mita, A. C., LoRusso, P. M., Burris, H. A., Hart, L. L., Low, S. C., Parsons, D. M., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2548 · Cited by 286
An injectable nanoparticle generator enhances delivery of cancer therapeutics
Xu, R., Zhang, G., Mai, J., Deng, X., Segura-Ibarra, V., Wu, S., Shen, J., Liu, H., Hu, Z., Chen, L., et al. (2016) · Nature Biotechnology · doi:10.1038/nbt.3506 · Cited by 280
Self-citationSafety of antisense oligonucleotide and siRNA-based therapeutics
Chi, X., Gatti, P., & Papoian, T. (2017) · Drug Discovery Today · doi:10.1016/j.drudis.2017.01.013 · Cited by 280
Schultheis, B., Strumberg, D., Santel, A., Vank, C., Gebhardt, F., Keil, O., Lange, C., Giese, K., Kaufmann, J., Khan, M., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.55.0376 · Cited by 260
Shaping nano-/micro-particles for enhanced vascular interaction in laminar flows
Lee, S.-Y., Ferrari, M., & Decuzzi, P. (2009) · Nanotechnology · doi:10.1088/0957-4484/20/49/495101 · Cited by 257
Self-citationFrontiers in cancer nanomedicine: directing mass transport through biological barriers
Ferrari, M. (2010) · Trends in Biotechnology · doi:10.1016/j.tibtech.2009.12.007 · Cited by 255
Self-citationEffective anti-tumor activity of oxaliplatin encapsulated in transferrin–PEG-liposome
Suzuki, R., Takizawa, T., Kuwata, Y., Mutoh, M., Ishiguro, N., Utoguchi, N., Shinohara, A., Eriguchi, M., Yanagie, H., & Maruyama, K. (2008) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2007.06.010 · Cited by 250
Nadano, D., Yasuda, T., & Kishi, K. (1993) · Clinical Chemistry · doi:10.1093/clinchem/39.3.448 · Cited by 236
Theranostic nanoparticles for future personalized medicine
Ryu, J. H., Lee, S., Son, S., Kim, S. H., Leary, J. F., Choi, K., & Kwon, I. C. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.04.027 · Cited by 222
Rugo, H. S., Barry, W. T., Moreno-Aspitia, A., Lyss, A. P., Cirrincione, C., Leung, E., Mayer, E. L., Naughton, M., Toppmeyer, D., Carey, L. A., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.5298 · Cited by 222
Selective delivery of doxorubicin to patients with breast carcinoma metastases by stealth liposomes
Symon, Z., Peyser, A., Tzemach, D., Lyass, O., Sucher, E., Shezen, E., & Gabizon, A. (1999) · Cancer · doi:10.1002/(sici)1097-0142(19990701)86:1<72::aid-cncr12>3.0.co;2-1 · Cited by 213
To heat or not to heat: Challenges with clinical translation of thermosensitive liposomes
Dou, Y., Hynynen, K., & Allen, C. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.01.025 · Cited by 210
Nanoparticle Albumin-Bound Paclitaxel: A Novel Cremphor-EL ® -Free Formulation of Paclitaxel
Stinchcombe, T. E. (2007) · Nanomedicine · doi:10.2217/17435889.2.4.415 · Cited by 205
Johannsen, M., Thiesen, B., Jordan, A., Taymoorian, K., Gneveckow, U., Waldöfner, N., Scholz, R., Koch, M., Lein, M., Jung, K., et al. (2005) · The Prostate · doi:10.1002/pros.20213 · Cited by 200
Clinical Pharmacology of Liposomal Anthracyclines: Focus on Pegylated Liposomal Doxorubicin
Solomon, R., & Gabizon, A. A. (2008) · Clinical Lymphoma and Myeloma · doi:10.3816/clm.2008.n.001 · Cited by 199
Discoidal Porous Silicon Particles: Fabrication and Biodistribution in Breast Cancer Bearing Mice
Godin, B., Chiappini, C., Srinivasan, S., Alexander, J. F., Yokoi, K., Ferrari, M., Decuzzi, P., & Liu, X. (2012) · Advanced Functional Materials · doi:10.1002/adfm.201200869 · Cited by 195
Self-citationStern, J. M., Kibanov Solomonov, V. V., Sazykina, E., Schwartz, J. A., Gad, S. C., & Goodrich, G. P. (2016) · International Journal of Toxicology · doi:10.1177/1091581815600170 · Cited by 194
Koukourakis, M. I., Koukouraki, S., Giatromanolaki, A., Archimandritis, S. C., Skarlatos, J., Beroukas, K., Bizakis, J. G., Retalis, G., Karkavitsas, N., & Helidonis, E. S. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.11.3512 · Cited by 191
Nanotherapy for Cancer: Targeting and Multifunctionality in the Future of Cancer Therapies
Ediriwickrema, A., & Saltzman, W. M. (2015) · ACS Biomaterials Science & Engineering · doi:10.1021/ab500084g · Cited by 183
Oligonucleotide Therapeutics — A New Class of Cholesterol-Lowering Drugs
Khvorova, A. (2017) · New England Journal of Medicine · doi:10.1056/nejmp1614154 · Cited by 183
Ramanathan, R. K., Korn, R. L., Raghunand, N., Sachdev, J. C., Newbold, R. G., Jameson, G., Fetterly, G. J., Prey, J., Klinz, S. G., Kim, J., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1990 · Cited by 183
The role of collagen crosslinks in ageing and diabetes - the good, the bad, and the ugly
Snedeker, J. G. (2014) · Muscles, Ligaments and Tendons Journal · doi:10.11138/mltj/2014.4.3.303 · Cited by 180
Myocet (liposome-encapsulated doxorubicin citrate): a new approach in breast cancer therapy
Batist, G., Barton, J., Chaikin, P., Swenson, C., & Welles, L. (2002) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.3.12.1739 · Cited by 179
Corrections to “Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies”
Naidoo, J., Page, D. B., Li, B. T., Connell, L. C., Schindler, K., Lacouture, M. E., Postow, M. A., & Wolchok, J. D. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw141 · Cited by 177
Nanovector delivery of siRNA for cancer therapy
Shen, H., Sun, T., & Ferrari, M. (2012) · Cancer Gene Therapy · doi:10.1038/cgt.2012.22 · Cited by 176
Self-citationWhat does physics have to do with cancer?
Michor, F., Liphardt, J., Ferrari, M., & Widom, J. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3092 · Cited by 176
Self-citationWeissmann, G. (1965) · New England Journal of Medicine · doi:10.1056/nejm196511112732006 · Cited by 174
Top‐down particle fabrication: control of size and shape for diagnostic imaging and drug delivery
Canelas, D. A., Herlihy, K. P., & DeSimone, J. M. (2009) · WIREs Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.40 · Cited by 173
Johnston, M., Semple, S. C., Klimuk, S. K., Edwards, K., Eisenhardt, M. L., Leng, E. C., Karlsson, G., Yanko, D., & Cullis, P. R. (2006) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2006.01.009 · Cited by 172
Clark, A. J., Wiley, D. T., Zuckerman, J. E., Webster, P., Chao, J., Lin, J., Yen, Y., & Davis, M. E. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1603018113 · Cited by 168
Moghimi, S. M., Andersen, A. J., Hashemi, S. H., Lettiero, B., Ahmadvand, D., Hunter, A. C., Andresen, T. L., Hamad, I., & Szebeni, J. (2010) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.04.003 · Cited by 167
Lancet, J. E., Uy, G. L., Cortes, J. E., Newell, L. F., Lin, T. L., Ritchie, E. K., Stuart, R. K., Strickland, S. A., Hogge, D., Solomon, S. R., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.15_suppl.7000 · Cited by 164
The Ribonuclease A Superfamily in Humans: Canonical RNases as the Buttress of Innate Immunity
Koczera, P., Märtin, L., Marx, G., & Schuerholz, T. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17081278 · Cited by 164
The preferential targeting of the diseased microvasculature by disk-like particles
Adriani, G., de Tullio, M. D., Mauro Ferrari, B., Hussain, F., Pascazio, G., Liu, X., & Decuzzi, P. (2012) · Biomaterials · doi:10.1016/j.biomaterials.2012.04.027 · Cited by 163
Wilop, S., von Hobe, S., Crysandt, M., Esser, A., Osieka, R., & Jost, E. (2009) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-009-0587-3 · Cited by 163
Glazer, E. S., Zhu, C., Massey, K. L., Thompson, C. S., Kaluarachchi, W. D., Hamir, A. N., & Curley, S. A. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2055 · Cited by 161
Targeted Cancer Therapy With Novel High Drug-Loading Nanocrystals
Liu, F., Park, J.-Y., Zhang, Y., Conwell, C., Liu, Y., Bathula, S. R., & Huang, L. (2010) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.22112 · Cited by 159
RNA-targeted therapeutics in cancer clinical trials: Current status and future directions
Barata, P. C., Sood, A. K., & Hong, D. S. (2016) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.08.004 · Cited by 159
Pasut, G., Paolino, D., Celia, C., Mero, A., Joseph, A. S., Wolfram, J., Cosco, D., Schiavon, O., Shen, H., & Fresta, M. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.12.008 · Cited by 158
Self-citationSessa, C., Guibal, A., Conte, G. D., & Rüegg, C. (2008) · Nature Clinical Practice Oncology · doi:10.1038/ncponc1150 · Cited by 157
Parameters Affecting the Enhanced Permeability and Retention Effect: The Need for Patient Selection
Natfji, A. A., Ravishankar, D., Osborn, H. M. I., & Greco, F. (2017) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2017.06.019 · Cited by 155
Remodeling Tumor Vasculature to Enhance Delivery of Intermediate-Sized Nanoparticles
Jiang, W., Huang, Y., An, Y., & Kim, B. Y. S. (2015) · ACS Nano · doi:10.1021/acsnano.5b02028 · Cited by 154
A chloroquine-induced macrophage-preconditioning strategy for improved nanodelivery
Wolfram, J., Nizzero, S., Liu, H., Li, F., Zhang, G., Li, Z., Shen, H., Blanco, E., & Mauro Ferrari, B. (2017) · Scientific Reports · doi:10.1038/s41598-017-14221-2 · Cited by 152
Self-citationRES blockade: A strategy for boosting efficiency of nanoparticle drug
Liu, T., Choi, H. S., Zhou, R., & Chen, I. (2015) · Nano Today · doi:10.1016/j.nantod.2014.12.003 · Cited by 148
Sevick, E., & Jain, R. K. (1989) · PubMed · Cited by 147
Designer combination therapy for cancer
Lane, D. P. (2006) · Nature Biotechnology · doi:10.1038/nbt0206-163 · Cited by 145
Fu, F., Nowak, M. A., & Bonhoeffer, S. (2015) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1004142 · Cited by 145
In situ detection of the protein corona in complex environments
Carril, M., Padró, D., del Pino, P., Carrillo‐Carrión, C., Gallego, M., & Parak, W. J. (2017) · Nature Communications · doi:10.1038/s41467-017-01826-4 · Cited by 145
In Vitro–In Vivo Translation of Lipid Nanoparticles for Hepatocellular siRNA Delivery
Whitehead, K. A., Matthews, J., Chang, P., Niroui, F., Dorkin, J. R., Severgnini, M., & Anderson, D. G. (2012) · ACS Nano · doi:10.1021/nn301922x · Cited by 143
Mifamurtide: A Review of its Use in the Treatment of Osteosarcoma
Frampton, J. E. (2010) · Pediatric Drugs · doi:10.2165/11204910-000000000-00000 · Cited by 139
Li, L., Sun, W. Y., Zhong, J., Yang, Q., Zhu, X. D., Zhou, Z., Zhang, Z., & Huang, Y. (2015) · Advanced Functional Materials · doi:10.1002/adfm.201501248 · Cited by 135
In search of the Holy Grail: Folate-targeted nanoparticles for cancer therapy
Garcia‐Bennett, A. E., Nees, M., & Fadeel, B. (2011) · Biochemical Pharmacology · doi:10.1016/j.bcp.2011.01.023 · Cited by 134
Parr, M. J., Ansell, S. M., Choi, L. S. L., & Cullis, P. R. (1994) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/0005-2736(94)90004-3 · Cited by 134
Crooke, S. T., Baker, B. F., Kwoh, T. J., Cheng, W., Schulz, D. J., Xia, S., Salgado, N. R., Bui, H., Hart, C. E., Burel, S. A., et al. (2016) · Molecular Therapy · doi:10.1038/mt.2016.136 · Cited by 133
Tumor Microenvironment-Responsive Multistaged Nanoplatform for Systemic RNAi and Cancer Therapy
Xu, X., Saw, P. E., Tao, W., Li, Y., Ji, X., Yu, M., Mahmoudi, M., Rasmussen, J., Ayyash, D., Zhou, Y., et al. (2017) · Nano Letters · doi:10.1021/acs.nanolett.7b01571 · Cited by 128
Systemic Lipoplatin infusion results in preferential tumor uptake in human studies.
Boulikas, T., Stathopoulos, G. P., Volakakis, N., & Vougiouka, M. (2005) · PubMed · Cited by 126
Keizman, D., Huang, P., Eisenberger, M. A., Пили, Р., Kim, J., Antonarakis, E. S., Hammers, H. J., & Carducci, M. A. (2011) · European Journal of Cancer · doi:10.1016/j.ejca.2011.04.019 · Cited by 126
Extracellular vesicle therapeutics for liver disease
Borrelli, D. A., Yankson, K., Shukla, N., Vilanilam, G. K., Ticer, T. D., & Wolfram, J. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.01.022 · Cited by 125
Self-citationProtease‐Triggered Unveiling of Bioactive Nanoparticles
Harris, T. J., von Maltzahn, G., Lord, M. E., Park, J., Agrawal, A., Min, D., Sailor, M. J., & Bhatia, S. N. (2008) · Small · doi:10.1002/smll.200701319 · Cited by 124
Contribution of Kupffer cells to liposome accumulation in the liver
Samuelsson, E., Shen, H., Blanco, E., Mauro Ferrari, B., & Wolfram, J. (2017) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2017.07.014 · Cited by 123
Self-citationTolcher, A. W., Papadopoulos, K. P., Patnaik, A., Rasco, D. W., Martinez, D., Wood, D. L., Fielman, B. A., Sharma, M., Janisch, L. A., Brown, B. D., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.15_suppl.11006 · Cited by 121
High Capacity Nanoporous Silicon Carrier for Systemic Delivery of Gene Silencing Therapeutics
Shen, J., Xu, R., Mai, J., Kim, H.-C., Guo, X., Qin, G., Yang, Y. P., Wolfram, J., Mu, C., Xia, X., et al. (2013) · ACS Nano · doi:10.1021/nn4035316 · Cited by 117
Self-citationPhosphorothioate backbone modifications of nucleotide-based drugs are potent platelet activators
Flierl, U., Nero, T. L., Lim, B., Arthur, J. F., Yao, Y., Jung, S. M., Gitz, E., Pollitt, A. Y., Zaldivia, M. T. K., Jandrot-Perrus, M., et al. (2015) · Journal of Experimental Medicine · doi:10.1084/jem.20140391 · Cited by 114
Salloum, R., Hummel, T. R., Kumar, S. S., Dorris, K. M. O., Li, S., Lin, T., Daryani, V. M., Stewart, C. F., Miles, L., Poussaint, T. Y., et al. (2016) · Journal of Neuro-Oncology · doi:10.1007/s11060-016-2189-7 · Cited by 107
Hybrid Collagenase Nanocapsules for Enhanced Nanocarrier Penetration in Tumoral Tissues
Villegas, M. R., Baeza, A., & Vallet‐Regí, M. (2015) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.5b07116 · Cited by 106
Design Maps for the Hyperthermic Treatment of Tumors with Superparamagnetic Nanoparticles
Cervadoro, A., Giverso, C., Pande, R., Sarangi, S., Preziosi, L., Wosik, J., Brazdeikis, A., & Decuzzi, P. (2013) · PLoS ONE · doi:10.1371/journal.pone.0057332 · Cited by 105
Xia, X., Mai, J., Xu, R., Perez, J. E. T., Guevara, M. L., Shen, Q., Mu, C., Tung, H.-Y., Corry, D. B., Evans, S. E., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.04.009 · Cited by 103
Marina, N. M., Cochrane, D., Harney, E., Zomorodi, K., Blaney, S. M., Winick, N. J., Bernstein, M. L., & Link, M. P. (2002) · PubMed · Cited by 101
O’Brien, J., & Shea, K. J. (2016) · Accounts of Chemical Research · doi:10.1021/acs.accounts.6b00125 · Cited by 101
Hwang, M., Jayakrishnan, T., Green, D. E., George, B., Thomas, J. P., Groeschl, R. T., Erickson, B. A., Pappas, S. G., Gamblin, T. C., & Turaga, K. K. (2014) · European Journal of Cancer · doi:10.1016/j.ejca.2014.03.277 · Cited by 98
Yokoi, K., Kojic, M., Milosevic, M., Tanei, T., Ferrari, M., & Ziemys, A. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-3494 · Cited by 95
Self-citationChau, Y., Dang, N. M., Tan, F. E., & Langer, R. (2006) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20548 · Cited by 94
Chloroquine and nanoparticle drug delivery: A promising combination
Pelt, J., Busatto, S., Mauro Ferrari, B., Thompson, E. A., Mody, K., & Wolfram, J. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.06.007 · Cited by 93
Self-citationHarrington, K. J., Rowlinson‐Busza, G., Syrigos, K. N., Abra, R. M., Uster, P. S., Peters, A. M., & Stewart, J. S. W. (2000) · British Journal of Cancer · doi:10.1054/bjoc.2000.1320 · Cited by 91
Intraoperative intravital microscopy permits the study of human tumour vessels
Fisher, D. T., Muhitch, J. B., Kim, M., Doyen, K. C., Bogner, P. N., Evans, S. S., & Skitzki, J. J. (2016) · Nature Communications · doi:10.1038/ncomms10684 · Cited by 90
Successful imaging of human cancer with indium-111-labeled phospholipid vesicles
Presant, C. A., Proffitt, R. T., Turner, A., Williams, L. E., Winsor, D. T., Werner, J. L., Kennedy, P., Wiseman, C. L., Gala, K. V., McKenna, R. J., et al. (1988) · Cancer · Cited by 89
Biophysical characterization of a liposomal formulation of cytarabine and daunorubicin
Dicko, A., Kwak, S., Frazier, A. A., Mayer, L. D., & Liboiron, B. D. (2010) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2010.02.014 · Cited by 87
Strategies for improving drug delivery: nanocarriers and microenvironmental priming
Khalid, A., Persano, S., Shen, H., Zhao, Y., Blanco, E., Ferrari, M., & Wolfram, J. (2016) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2017.1243527 · Cited by 82
Self-citationPresant, C. A., Blayney, D. W., Kennedy, P., Wiseman, C. L., Gala, K. V., Presant, S., Proffitt, R. T., Crossley, R. J., Preiss, S. J., Ksionski, G., et al. (1990) · The Lancet · doi:10.1016/0140-6736(90)91188-g · Cited by 79
Blanco, E., Sangai, T., Wu, S., Hsiao, A., Ruiz‐Esparza, G. U., González-Delgado, C. A., Cara, F. E., Granados-Principal, S. M., Evans, K. W., Akçakanat, A., et al. (2014) · Molecular Therapy · doi:10.1038/mt.2014.27 · Cited by 78
Self-citationHuman Autologous Tumor-Specific T-Cell Responses Induced by Liposomal Delivery of a Lymphoma Antigen
Neelapu, S. S., Baskar, S., Gause, B. L., Kobrin, C. B., Watson, T. M., Frye, A. R., Pennington, R., Harvey, L. K., Jaffe, E. S., Robb, R. J., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1071 · Cited by 77
Liposomal Irinotecan: A Review in Metastatic Pancreatic Adenocarcinoma
Lamb, Y. N., & Scott, L. J. (2017) · Drugs · doi:10.1007/s40265-017-0741-1 · Cited by 76
Multistage delivery of chemotherapeutic nanoparticles for breast cancer treatment
Blanco, E., Sangai, T., Hsiao, A., Ferrati, S., Bai, L., Liu, X., Meric‐Bernstam, F., & Ferrari, M. (2012) · Cancer Letters · doi:10.1016/j.canlet.2012.07.027 · Cited by 74
Self-citationGentile, E., Cilurzo, F., Marzio, L. D., Carafa, M., Ventura, C. A., Wolfram, J., Paolino, D., & Celia, C. (2013) · Future Oncology · doi:10.2217/fon.13.146 · Cited by 73
Self-citationPolyethylenimine and chitosan carriers for the delivery of RNA interference effectors
Molinaro, R., Wolfram, J., Federico, C., Cilurzo, F., Marzio, L. D., Ventura, C. A., Carafa, M., Celia, C., & Fresta, M. (2013) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2013.840286 · Cited by 72
Self-citationKirui, D. K., Celia, C., Molinaro, R., Bansal, S. S., Cosco, D., Fresta, M., Shen, H., & Mauro Ferrari, B. (2015) · Advanced Healthcare Materials · doi:10.1002/adhm.201400738 · Cited by 70
Yokoi, K., Tanei, T., Godin, B., van de Ven, A. L., Hanibuchi, M., Matsunoki, A., Alexander, J. F., & Mauro Ferrari, B. (2013) · Cancer Letters · doi:10.1016/j.canlet.2013.11.015 · Cited by 67
Negligible absorption of radiofrequency radiation by colloidal gold nanoparticles
Li, D., Jung, Y. S., Tan, S., Kim, H. K., Chory, E., & Geller, D. A. (2011) · Journal of Colloid and Interface Science · doi:10.1016/j.jcis.2011.01.059 · Cited by 66
Gadolinium Chloride Augments Tumor-Specific Imaging of Targeted Quantum Dots In Vivo
Diagaradjane, P., Deorukhkar, A., Gelovani, J. G., Maru, D. M., & Krishnan, S. (2010) · ACS Nano · doi:10.1021/nn901919w · Cited by 65
Bankruptcy filing worries developers of nanoparticle cancer drugs
Ledford, H. K. (2016) · Nature · doi:10.1038/533304a · Cited by 65
Broering, R., Real, C. I., John, M., Jahn‐Hofmann, K., Ickenstein, L. M., Kleinehr, K., Paul, A., Sutter, K., Dittmer, U., Gerken, G., et al. (2013) · International Immunology · doi:10.1093/intimm/dxt040 · Cited by 62
Evolutionary changes to transthyretin: structure–function relationships
Prapunpoj, P., & Leelawatwattana, L. (2009) · FEBS Journal · doi:10.1111/j.1742-4658.2009.07243.x · Cited by 61
Multistage vector (MSV) therapeutics
Wolfram, J., Shen, H., & Mauro Ferrari, B. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.010 · Cited by 60
Self-citationA Micro/Nano Composite for Combination Treatment of Melanoma Lung Metastasis
Mi, Y., Mu, C., Wolfram, J., Deng, Z., Hu, Y., Liu, X., Blanco, E., Shen, H., & Mauro Ferrari, B. (2016) · Advanced Healthcare Materials · doi:10.1002/adhm.201500910 · Cited by 57
Self-citationPost-nano strategies for drug delivery: multistage porous silicon microvectors
Venuta, A., Wolfram, J., Shen, H., & Mauro Ferrari, B. (2016) · Journal of Materials Chemistry B · doi:10.1039/c6tb01978a · Cited by 57
Self-citationPolycation-functionalized nanoporous silicon particles for gene silencing on breast cancer cells
Zhang, M., Xu, R., Xia, X., Yang, Y., Gu, J., Qin, G., Liu, X., Mauro Ferrari, B., & Shen, H. (2013) · Biomaterials · doi:10.1016/j.biomaterials.2013.09.033 · Cited by 56
Nakai, Y., Isayama, H., Ijichi, H., Sasaki, T., Takahara, N., Ito, Y., Matsubara, S., Uchino, R., Yagioka, H., Arizumi, T., et al. (2013) · Investigational New Drugs · doi:10.1007/s10637-013-9972-5 · Cited by 54
Alnylam terminates revusiran program, stock plunges
Garber, K. (2016) · Nature Biotechnology · doi:10.1038/nbt1216-1213 · Cited by 53
Taking the vehicle out of drug delivery
Shen, J., Wolfram, J., Mauro Ferrari, B., & Shen, H. (2017) · Materials Today · doi:10.1016/j.mattod.2017.01.013 · Cited by 53
Self-citationCervantes, A. M. R., Alsina, M., Tabernero, J. M., Infante, J. R., LoRusso, P. M., Shapiro, G. I., Paz-Ares, L. G., Falzone, R., Hill, J., Cehelsky, J., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.29.15_suppl.3025 · Cited by 53
Nanotechnology based therapeutic modality to boost anti-tumor immunity and collapse tumor defense
Hu, X., Wu, T., Bao, Y., & Zhang, Z. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.04.026 · Cited by 52
Theis, T., Parr, D., Binks, P., Ying, J. Y., Drexler, K. E., Schepers, E., Mullis, K. B., Bai, C., Boland, J. J., Langer, R., et al. (2006) · Nature Nanotechnology · doi:10.1038/nnano.2006.77 · Cited by 51
Self-citationLessons from immuno-oncology: a new era for cancer nanomedicine?
Jiang, W., Yuan, H., Chan, C. K. F., Roemeling, C. A. V., Yan, Z., Weissman, I. L., & Kim, B. Y. S. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.34 · Cited by 44
Shen, H., Sun, T., Hoang, H. H., Burchfield, J. S., Hamilton, G. F., Mittendorf, E. A., & Ferrari, M. (2017) · Seminars in Immunology · doi:10.1016/j.smim.2017.09.002 · Cited by 37
Self-citationPorous Silicon Microparticles for Delivery of siRNA Therapeutics
Shen, J., Wu, X., Lee, Y., Wolfram, J., Yang, Z., Mao, Z., Mauro Ferrari, B., & Shen, H. (2015) · Journal of Visualized Experiments · doi:10.3791/52075 · Cited by 36
Self-citationMérian, J., Souza, R. D., Dou, Y. N., Ekdawi, S. N., Ravenelle, F., & Allen, C. J. (2015) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2015.04.060 · Cited by 22
Alexis, F. (2014) · Molecular Therapy · doi:10.1038/mt.2014.96 · Cited by 14
FDA approves DaunoXome as first-line therapy for Kaposi's sarcoma. Food and Drug Administration.
(1996) · PubMed · Cited by 14
Transport Oncophysics in silico, in vitro, and in vivo
Koay, E. J., & Mauro Ferrari, B. (2014) · Physical Biology · doi:10.1088/1478-3975/11/6/060201 · Cited by 12
Pauthner, M. G., Yeung, J., Ullman, C., Bakker, J., Wurch, T., Reichert, J. M., Lund‐Johansen, F., Bradbury, A. M., Carter, P. J., & Melis, J. P. M. (2016) · mAbs · doi:10.1080/19420862.2016.1153211 · Cited by 9
Cited by
Current advance of nanotechnology in diagnosis and treatment for malignant tumors
Wang, B., Hu, S., Teng, Y., Chen, J., Wang, H., Xu, Y., Wang, K., Xu, J., Cheng, Y., & Gao, X. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01889-y · Cited by 558
Moradi Kashkooli, F., Soltani, M., & Souri, M. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.08.012 · Cited by 514
Engineering mesoporous silica nanoparticles for drug delivery: where are we after two decades?
Vallet-Regí, M., Schüth, F., Lozano, D., Colilla, M., & Manzano, M. (2022) · Chemical Society Reviews · doi:10.1039/d1cs00659b · Cited by 507
Extracellular vesicle-based drug delivery systems for cancer treatment
Walker, S., Busatto, S., Pham, A., Tian, M., Suh, A., Carson, K., Quintero, A., Lafrence, M., Malik, H., Santana, M. X., et al. (2019) · Theranostics · doi:10.7150/thno.37097 · Cited by 429
Self-citationSupramolecular cancer nanotheranostics
Zhou, J., Rao, L., Yu, G., Cook, T. R., Chen, X., & Huang, F. (2021) · Chemical Society Reviews · doi:10.1039/d0cs00011f · Cited by 411
Metadata
- Authors
- Wolfram, J., & Ferrari, M.
- Venue
- Nano Today
- Publisher
- Elsevier BV
- Published
- 2019-04
- Volume
- 25
- Pages
- 85-98
- ISSN
- 1748-0132 (ISSN-L)
- OpenAlex
- W2921868990
- Cited by
- 436
- References
- 198
- FWCI
- 16.37
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.